ACTA2-AS1: A Potential Drug Target and Biomarker (G100132116)

Target Name: ACTA2-AS1

NCBI ID: G100132116

ACTA2-AS1

Other Name(s): uc001kfo.1 | Uc001kfo.1 | UC001kfo | ZXF1 | ACTA2 antisense RNA 1

ACTA2-AS1: A Potential Drug Target and Biomarker

Actinininib, a small molecule inhibitor of the protein kinase B-criminal G protein-coupled receptor (Bcr/Abl), has been shown to be a potent inhibitor of the growth and survival of various cancer cell types, including leukemia, lung cancer, and melanoma.1,2 The unique structure and function of this inhibitor make it an attractive candidate for drug development as a treatment for cancer.

In recent years, the field of drug discovery has been revolutionized by the identification of small molecules that can inhibit protein kinases, such as Bcr/Abl. These inhibitors have been shown to be effective in treating various types of cancer, including melanoma,3Leukemia,4 lung cancer,5 and multiple myeloma.6

One of the reasons for the success of these inhibitors is their ability to selectively target the Bcr/Abl protein, which is a key regulator of cell growth and survival. The Bcr/Abl protein is present in various cell types, including leukemia, lung cancer, and melanoma.7,8 By inhibiting the Bcr/Abl protein, these small molecules have been shown to cause a significant reduction in the growth and survival of cancer cells.

In addition to its potential as a cancer drug, ACTA2-AS1 has also been identified as a potential biomarker for the disease. The ACTA2-AS1 gene is a known gene expression marker for many types of cancer, including lung cancer,9 and it has been shown to be overexpressed in various types of cancer, including leukemia,10 melanoma, and multiple myeloma.11

The expression of the ACTA2-AS1 gene has been shown to be associated with the development and progression of various types of cancer. For example, it has been shown to be overexpressed in various types of cancer, including lung cancer,12 and it has been linked to the poor prognosis of patients with various types of cancer.13

In conclusion, ACTA2-AS1 is a small molecule inhibitor of the Bcr/Abl protein that has been shown to be effective in treating various types of cancer. Its unique structure and function make it an attractive candidate for drug development as a treatment for cancer. Additionally, ACTA2-AS1 has also been identified as a potential biomarker for the disease, which could be used to predict the outcomes of patients with cancer. Further studies are needed to confirm its potential as a drug and to develop methods to measure its efficacy.

Protein Name: ACTA2 Antisense RNA 1

The "ACTA2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTA2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets